Mark Brister - Net Worth and Insider Trading

Mark Brister Net Worth

The estimated net worth of Mark Brister is at least $14 Million dollars as of 2024-12-27. Mark Brister is the VP Advanced Development Teams of DexCom Inc and owns about 175,472 shares of DexCom Inc (DXCM) stock worth over $14 Million. Mark Brister is also the Chief Technology Officer of Obalon Therapeutics Inc and owns about 12,955 shares of Obalon Therapeutics Inc (OBLN) stock worth over $39,513. Details can be seen in Mark Brister's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Brister has not made any transactions after 2019-08-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mark Brister

To

Mark Brister Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Brister owns 3 companies in total, including Obalon Therapeutics Inc (OBLN) , DexCom Inc (DXCM) , and Reshape Lifesciences Inc (RSLS) .

Click here to see the complete history of Mark Brister’s form 4 insider trades.

Insider Ownership Summary of Mark Brister

Ticker Comapny Transaction Date Type of Owner
OBLN Obalon Therapeutics Inc 2020-01-24 Chief Technology Officer
DXCM DexCom Inc 2006-05-02 VP & Advanced Development Teams
RSLS Reshape Lifesciences Inc 2016-10-05 VP of Research and Development

Mark Brister Latest Holdings Summary

Mark Brister currently owns a total of 2 stocks. Among these stocks, Mark Brister owns 175,472 shares of DexCom Inc (DXCM) as of May 2, 2006, with a value of $14 Million and a weighting of 99.72%. Mark Brister also owns 12,955 shares of Obalon Therapeutics Inc (OBLN) as of August 6, 2019, with a value of $39,513 and a weighting of 0.28%.

Latest Holdings of Mark Brister

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DXCM DexCom Inc 2006-05-02 175,472 80.57 14,137,779
OBLN Obalon Therapeutics Inc 2019-08-06 12,955 3.05 39,513

Holding Weightings of Mark Brister


Mark Brister Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Brister has made a total of 0 transactions in DexCom Inc (DXCM) over the past 5 years. The most-recent trade in DexCom Inc is the sale of 800,000 shares on May 2, 2006, which brought Mark Brister around $1 Million.

According to the SEC Form 4 filings, Mark Brister has made a total of 0 transactions in Obalon Therapeutics Inc (OBLN) over the past 5 years. The most-recent trade in Obalon Therapeutics Inc is the acquisition of 1,667 shares on August 6, 2019, which cost Mark Brister around $20,000.

Insider Trading History of Mark Brister

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Brister Trading Performance

GuruFocus tracks the stock performance after each of Mark Brister's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Brister is -43.38%. GuruFocus also compares Mark Brister's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Brister within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Brister's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Brister

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -43.38 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -46.74 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Brister Ownership Network

Ownership Network List of Mark Brister

No Data

Ownership Network Relation of Mark Brister

Insider Network Chart

Mark Brister Owned Company Details

What does Obalon Therapeutics Inc do?

Who are the key executives at Obalon Therapeutics Inc?

Mark Brister is the Chief Technology Officer of Obalon Therapeutics Inc. Other key executives at Obalon Therapeutics Inc include director & President & CEO & Exec Chairman Andrew P Rasdal , Chief Financial Officer Nooshin Hussainy , and Chief Retail Officer Robert J Macdonald .

Obalon Therapeutics Inc (OBLN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Obalon Therapeutics Inc (OBLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Obalon Therapeutics Inc (OBLN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Obalon Therapeutics Inc (OBLN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Obalon Therapeutics Inc Insider Transactions

No Available Data

Mark Brister Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Brister. You might contact Mark Brister via mailing address: C/o Dexcom, Inc., 5555 Oberlin Drive, San Diego Ca 92121.

Discussions on Mark Brister

No discussions yet.